针对肺癌中的HER2:不断发展的治疗环境和药物开发策略
Daniel Reinhorn1,2,3, Mor Moskovitz2,3, William D Tap1,4
1Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Cancer
|April 2, 2025
概括
现在Trastuzumab deruxtecan已经获得FDA的批准,用于治疗HER2突变非小细胞肺癌 (NSCLC). 这种抗体-药物结合体对HER2改变的固体瘤有前途,推进了瘤不可知治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在非小细胞肺癌 (NSCLC) 中,ERBB2 (HER2) 变化是关键标.
- 目前的一线NSCLC治疗是化疗+/-免疫疗法.
- 针对HER2的疗法表现出不同的疗效,抗体-药物合物作为有前途的选择.
研究的目的:
- 审查NSCLC中的HER2变异及其临床影响.
- 提供当前HER2向治疗领域的概述.
- 总结针对HER2向治疗的关键和正在进行的临床试验,包括瘤不可知的方法.
主要方法:
- 关于NSCLC中HER2变化的科学文献的综述.
- 对HER2向治疗的临床试验数据的分析.
- 讨论FDA批准和瘤不可知药物的开发.
主要成果:
- 特拉斯图祖马布德鲁克斯泰坎 (T-DXd) 是第一个FDA批准的治疗预先治疗的HER2突变NSCLC的疗法.
- 在DESTINY-肺和DESTINY-泛瘤试验中,T-DXd已经证明了它的有效性.
- T-DXd获得了全瘤FDA批准用于HER2阳性固体瘤.
结论:
- 在NSCLC中,HER2的改变是显著的,影响了预后和治疗反应.
- 特拉斯图祖马布德鲁克斯泰坎代表了HER2向性NSCLC治疗的突破.
- 瘤不可知药物开发策略对HER2改变的癌症有很大的潜力.
关键词:
在HER2放大时,HER2放大.这是一个HER2突变.在HER2过度表达的过程中,抗体药物合物 抗体药物合物非小细胞肺癌的肺癌.整体瘤是一个瘤.有针对性的治疗.铁氨基激酶抑制剂 铁氨基激酶抑制剂更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.1K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
990
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...